Association of a polymorphism in a gene encoding a urate transporter with ckd progression

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 6, 2014, Pages 1059-1065

  Testa, Alessandra ^a   Mallamaci, Francesca ^a   Spoto, Belinda ^a   Pisano, Anna ^a   Cristina Sanguedolce, Maria ^a   Tripepi, Giovanni ^a   Leonardis, Daniela ^a   Zoccali, Carmine ^a  

^a CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALLOPURINOL; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENOMIC DNA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE; TRIACYLGLYCEROL; URATE TRANSPORTER; URIC ACID; GLUCOSE TRANSPORTER; SLC2A9 PROTEIN, HUMAN;

ADULT; AGED; ALLELE; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; BODY MASS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DNA EXTRACTION; FEMALE; FOLLOW UP; GENDER; GENE; GENETIC ASSOCIATION; GENOTYPE; GLOMERULUS FILTRATION RATE; HEART RATE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PROSPECTIVE STUDY; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; URATE TRANSPORTER GENE; URIC ACID BLOOD LEVEL; VALIDITY; BLOOD; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; GENE FREQUENCY; GENETICS; MIDDLE AGED; PATHOPHYSIOLOGY; PROTEINURIA; YOUNG ADULT;

ADULT; AGED; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; URIC ACID; YOUNG ADULT;

EID: 84922012542     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.11041013     Document Type: Article

References (33)

1. Johnson RJ, Nakagawa T, Jalal D, Sànchez-Lozada LG, Kang DH, Ritz E: Uric acid and chronic kidney disease: Which is chasing which? Nephrol Dial Transplant 28: 2221–2228, 2013.
2. Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, Kestenbaum B, Carney JK, Fried LF: Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 50: 239–247, 2007.
3. Park JT, Kim DK, Chang TI, Kim HW, Chang JH, Park SY, Kim E, Kang SW, Han DS, Yoo TH: Uric acid is associatedwith the rate of residual renal function decline in peritoneal dialysis patients. Nephrol Dial Transplant 24: 3520–3525, 2009.
4. Chang HY, Tung CW, Lee PH, Lei CC, Hsu YC, Chang HH, Yang HF, Lu LC, Jong MC, Chen CY, Fang KY, Chao YS, Shih YH, Lin CL: Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population. Am J Med Sci 339: 509–515, 2010.
5. Syrjänen J, Mustonen J, Pasternack A: Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 15: 34–42, 2000.
6. Sturm G, Kollerits B, Neyer U, Ritz E, Kronenberg F; MMKD Study Group: Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol 43: 347–352, 2008.
7. Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, Collins AJ, Levey AS, Menon V: Uric acid and long-term outcomes in CKD. Am J Kidney Dis 53: 796–803, 2009.
8. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, Uz E, Akcay A, Yigitoglu R, Covic A: Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol 39: 1227–1233, 2007.
9. Siu YP, Leung KT, Tong MK, Kwan TH: Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47: 51–59, 2006.
10. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, Arroyo D, Luño J: Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5: 1388–1393, 2010.
11. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ: A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13: 2888–2897, 2002.
12. Nakagawa T, Mazzali M, Kang DH, Kanellis J, Watanabe S, Sanchez-Lozada LG, Rodriguez-Iturbe B, Herrera-Acosta J, Johnson RJ: Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 23: 2–7, 2003.
13. Sànchez-Lozada LG, Tapia E, Avila-Casado C, Soto V, Franco M, Santamaría J, Nakagawa T, Rodríguez-Iturbe B, Johnson RJ, Herrera-Acosta J: Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 283: F1105–F1110, 2002.
14. Sakurai H: Urate transporters in the genomic era. Curr Opin Nephrol Hypertens 22: 545–550, 2013.
15. Bobulescu IA, Moe OW: Renal transport of uric acid: Evolving concepts and uncertainties. Adv Chronic Kidney Dis 19: 358–371, 2012.
16. Matsuo H, Chiba T, Nagamori S, Nakayama A, Domoto H, Phetdee K, Wiriyasermkul P, Kikuchi Y, Oda T, Nishiyama J, Nakamura T, Morimoto Y, Kamakura K, Sakurai Y, Nonoyama S, Kanai Y, Shinomiya N: Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet 83: 744–751, 2008.
17. Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M, Mangino M, Albrecht E, Wallace C, Farrall M, Johansson A, Nyholt DR, Aulchenko Y, Beckmann JS, Bergmann S, Bochud M, Brown M, Campbell H; EUROSPAN Consortium Connell J, Dominiczak A, Homuth G, Lamina C, McCarthy MI; ENGAGE Consortium Meitinger T, Mooser V, Munroe P, Nauck M, Peden J, Prokisch H, Salo P, Salomaa V, Samani NJ, Schlessinger D, Uda M, Völker U, Waeber G, Waterworth D, Wang-Sattler R, Wright AF, Adamski J, Whitfield JB, Gyllensten U, Wilson JF, Rudan I, Pramstaller P, Watkins H; ROCARDIS Consortium Doering A, Wichmann HE; KORA Study Spector TD, Peltonen L, Völzke H, Nagaraja R, Vollenweider P, Caulfield M; WTCCCIllig T, Gieger C: Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 5: e1000504, 2009.
18. Smith GD, Ebrahim S: ‘Mendelian randomization’: Can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32: 1–22, 2003.
19. Steyerberg EW: Clinical Prediction Models: APractical Approach to Development, Validation, and Updating (Statistics for Biology and Health), 1st Ed., New York, pringer, 2009.
20. Feig DI: Uric acid: A novel mediator andmarker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens 18: 526–530, 2009.
21. Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S: Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 24: 691–697, 2001.
22. Domrongkitchaiporn S, Sritara P, Kitiyakara C, Stitchantrakul W, Krittaphol V, Lolekha P, Cheepudomwit S, Yipintsoi T: Risk factors for development of decreased kidney function in a southeast Asian population: A 12-year cohort study. J Am Soc Nephrol 16: 791–799, 2005.
23. Obermayr RP, Temml C, Knechtelsdorfer M, Gutjahr G, Kletzmayr J, Heiss S, Ponholzer A, Madersbacher S, Oberbauer R, Klauser-Braun R: Predictors of new-onset decline in kidney function in a general middle-European population. Nephrol Dial Transplant 23: 1265–1273, 2008.
24. Weiner DE, Tighiouart H, Elsayed EF,Griffith JL, Salem DN, Levey AS:Uric acid and incident kidney disease in the community. J Am Soc Nephrol 19: 1204–1211, 2008.
25. Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS: Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 169: 342–350, 2009.
26. Bellomo G, Venanzi S, Verdura C, Saronio P, Esposito A, Timio M: Association of uric acidwith change in kidney function in healthy normotensive individuals. Am J Kidney Dis 56: 264–272, 2010.
27. Hovind P, Rossing P, Tarnow L, Johnson RJ, Parving HH: Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: An inception cohort study. Diabetes 58: 1668–1671, 2009.
28. Tseng CH: Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetesmellitus in Taiwan. Kidney Int 68: 796–801, 2005.
29. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE: Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 51: 1908–1919, 1997.
30. Preitner F, Bonny O, Laverrière A, Rotman S, Firsov D, Da Costa A, Metref S, Thorens B: Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proc Natl Acad Sci U S A 106: 15501–15506, 2009.
31. Parsa A, Brown E, Weir MR, Fink JC, Shuldiner AR, Mitchell BD, McArdle PF: Genotype-based changes in serum uric acid affect blood pressure. Kidney Int 81: 502–507, 2012.
32. Wang J, Shete S: A test for genetic association that incorporates information about deviation from Hardy-Weinberg proportions in cases. Am J Hum Genet 83: 53–63, 2008.
33. Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, Feldman HI, Parekh RS, Kusek JW, Greene TH, Fink JC, Anderson AH, Choi MJ, Wright JT Jr, Lash JP, Freedman BI, Ojo A, Winkler CA, Raj DS, Kopp JB, He J, Jensvold NG, Tao K, Lipkowitz MS, Appel LJ; AASK Study Investigators; CRIC Study Investigators: APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 369: 2183–2196, 2013.